Annals of Oncology 15:1261-1266, 2004
© 2004 European Society for Medical Oncology
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma
Background: Tumor angiogenesis, or new blood vessel formation, is regulated by a balance between pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and anti-angiogenic factors such as endostatin.Patients and methods: To investigate this angiogenic balance in soft tissue sarcomas (STS), blood samples were collected from 76 STS patients and 15 healthy controls, and analyzed for VEGF, bFGF and endostatin using quantitative enzyme-linked immunosorbent assays (ELISA).
Results: Forty-one patients (54%) had primary tumors, 20 (26%) had local recurrences and 15 (20%) had metastatic disease with or without local disease. Levels of all three angiogenic factors were highly variable in STS patients. Mean levels of VEGF and bFGF were 12 and 14 times higher, respectively, in patients compared with controls (P<0.0001). VEGF levels correlated with size of tumor, with the highest levels found in tumors >10 cm in size. Patients with metastases had endostatin levels 45% lower than patients without metastases (P=0.047). In 54 patients who underwent resection of primary disease or local recurrence, low pre-operative bFGF level was associated with a higher risk of subsequent recurrence (P=0.044).
Conclusions: STS secrete widely variable levels of angiogenic factors, and levels of specific factors may correlate with extent of disease, predict risk of recurrence and possibly guide the use of anti-angiogenic agents.
1 Sarcoma Disease Management Team, Department of Surgery and 2 Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
* Correspondence to: Dr S. Singer, Sarcoma Disease Management Team, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Tel: +1-212-639-2940; Fax: +1-212-717-3053; Email: singers{at}mskcc.org
Key words: angiogenesis, basic fibroblast growth factor, endostatin, soft tissue sarcoma, vascular endothelial growth factor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne, M. Scurr, P. Schoffski, F. Collin, L. Pandite, S. Marreaud, A. De Brauwer, et al. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) J. Clin. Oncol., July 1, 2009; 27(19): 3126 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Baker, E. K. Rowinsky, D. Mendelson, R. A. Humerickhouse, R. A. Knight, J. Qian, R. A. Carr, G. B. Gordon, and G. D. Demetri Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma J. Clin. Oncol., December 1, 2008; 26(34): 5583 - 5588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sleijfer, W. T.A. van der Graaf, and J.-Y. Blay Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas Oncologist, November 1, 2008; 13(11): 1193 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, J. A.F. Hannay, J. Liu, P. Das, M. Zhan, T. Nguyen, D. J. Hicklin, D. Yu, R. E. Pollock, and D. Lev Vascular Endothelial Growth Factor Overexpression by Soft Tissue Sarcoma Cells: Implications for Tumor Growth, Metastasis, and Chemoresistance. Cancer Res., September 1, 2006; 66(17): 8770 - 8778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. D'Adamo, S. E. Anderson, K. Albritton, J. Yamada, E. Riedel, K. Scheu, G. K. Schwartz, H. Chen, and R. G. Maki Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas J. Clin. Oncol., October 1, 2005; 23(28): 7135 - 7142. [Abstract] [Full Text] [PDF]
|
|